Top-Rated StocksTop-RatedNASDAQ:INSM Insmed (INSM) Stock Price, News & Analysis $79.38 -0.54 (-0.68%) Closing price 04:00 PM EasternExtended Trading$80.31 +0.93 (+1.18%) As of 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Insmed Stock (NASDAQ:INSM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Insmed alerts:Sign Up Key Stats Today's Range$78.85▼$81.5050-Day Range$68.29▼$83.8352-Week Range$21.92▼$84.91Volume1.34 million shsAverage Volume2.18 million shsMarket Capitalization$14.37 billionP/E RatioN/ADividend YieldN/APrice Target$94.00Consensus RatingBuy Company OverviewInsmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.Read More… Remove Ads Insmed Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks74th Percentile Overall ScoreINSM MarketRank™: Insmed scored higher than 74% of companies evaluated by MarketBeat, and ranked 239th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingInsmed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 16 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageInsmed has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Insmed's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Insmed are expected to grow in the coming year, from ($4.56) to ($2.89) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Insmed is -14.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Insmed is -14.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Insmed's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.57% of the float of Insmed has been sold short.Short Interest Ratio / Days to CoverInsmed has a short interest ratio ("days to cover") of 7.6.Change versus previous monthShort interest in Insmed has recently increased by 1.11%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInsmed does not currently pay a dividend.Dividend GrowthInsmed does not have a long track record of dividend growth. Sustainability and ESG4.3 / 5Environmental Score-1.58 Percentage of Shares Shorted8.57% of the float of Insmed has been sold short.Short Interest Ratio / Days to CoverInsmed has a short interest ratio ("days to cover") of 7.6.Change versus previous monthShort interest in Insmed has recently increased by 1.11%, indicating that investor sentiment is decreasing. News and Social Media2.7 / 5News Sentiment0.93 News SentimentInsmed has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 23 news articles for Insmed this week, compared to 10 articles on an average week.Search InterestOnly 7 people have searched for INSM on MarketBeat in the last 30 days. This is a decrease of -42% compared to the previous 30 days.MarketBeat FollowsOnly 8 people have added Insmed to their MarketBeat watchlist in the last 30 days. This is a decrease of -27% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Insmed insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $42,992,528.00 in company stock.Percentage Held by InsidersOnly 4.60% of the stock of Insmed is held by insiders.Read more about Insmed's insider trading history. Receive INSM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Insmed and its competitors with MarketBeat's FREE daily newsletter. Email Address INSM Stock News HeadlinesInsmed (NASDAQ:INSM) Price Target Raised to $96.00 at Bank of AmericaMarch 23 at 3:33 AM | americanbankingnews.comInsmed's (INSM) Outperform Rating Reiterated at Royal Bank of CanadaMarch 22 at 2:41 AM | americanbankingnews.comThis could put Trump on new $100 billAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Washington. Its purpose: to put Donald Trump’s face on the $100 note. All to celebrate a new “golden age” for America. March 24, 2025 | Paradigm Press (Ad)Insmed price target raised to $96 from $92 at BofAMarch 21 at 3:27 PM | markets.businessinsider.com3INSM : Expert Outlook: Insmed Through The Eyes Of 13 AnalystsMarch 19, 2025 | benzinga.comInsmed (INSM) Gets a Buy from Mizuho SecuritiesMarch 19, 2025 | markets.businessinsider.comInsmed Incorporated (INSM): Among the Best Biotech Stocks to Buy According to BillionairesMarch 18, 2025 | msn.comIs Insmed Incorporated (INSM) a Best Biotech Stock According to Billionaires?March 17, 2025 | insidermonkey.comSee More Headlines INSM Stock Analysis - Frequently Asked Questions How have INSM shares performed this year? Insmed's stock was trading at $69.04 on January 1st, 2025. Since then, INSM stock has increased by 15.0% and is now trading at $79.38. View the best growth stocks for 2025 here. How were Insmed's earnings last quarter? Insmed Incorporated (NASDAQ:INSM) released its earnings results on Thursday, February, 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.17) by $0.15. The biopharmaceutical company earned $104.44 million during the quarter, compared to analyst estimates of $102.31 million. Insmed had a negative net margin of 251.24% and a negative trailing twelve-month return on equity of 4,773.73%. Who are Insmed's major shareholders? Insmed's top institutional shareholders include Vanguard Group Inc. (10.18%), Darwin Global Management Ltd. (7.24%), Price T Rowe Associates Inc. MD (7.10%) and Capital International Investors (3.98%). Insiders that own company stock include William Lewis, Melvin Md Sharoky, Roger Adsett, John Drayton Wise, Sara Bonstein, Martina MD Flammer, Orlov S Nicole Schaeffer and Michael Alexander Smith. View institutional ownership trends. How do I buy shares of Insmed? Shares of INSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Insmed own? Based on aggregate information from My MarketBeat watchlists, some other companies that Insmed investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), CrowdStrike (CRWD), Advanced Micro Devices (AMD) and Arista Networks (ANET). Company Calendar Last Earnings2/20/2025Today3/24/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:INSM CIK1104506 Webwww.insmed.com Phone908-977-9900Fax732-438-0381Employees373Year FoundedN/APrice Target and Rating Average Stock Price Target$94.00 High Stock Price Target$110.00 Low Stock Price Target$63.00 Potential Upside/Downside+17.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)($5.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-749,570,000.00 Net Margins-251.24% Pretax Margin-251.01% Return on Equity-4,773.73% Return on Assets-54.58% Debt Debt-to-Equity Ratio2.03 Current Ratio6.37 Quick Ratio5.99 Sales & Book Value Annual Sales$363.71 million Price / Sales39.88 Cash FlowN/A Price / Cash FlowN/A Book Value($2.32) per share Price / Book-34.54Miscellaneous Outstanding Shares180,999,000Free Float170,673,000Market Cap$14.51 billion OptionableOptionable Beta1.28 Social Links A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:INSM) was last updated on 3/24/2025 by MarketBeat.com Staff From Our PartnersTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredMusk’s real agenda in D.C. Companies connected to Elon’s new map of America are making major climbs in price. And on May 30, the next wav...Porter & Company | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insmed Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Insmed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.